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The global pandemic of COVID-19 pneumonia caused by the novel coronavirus (SARS-CoV-2) has strained
healthcare resources across the world with emerging challenges of mass testing, resource allocation and man
agement. While reverse transcriptase-polymerase chain reaction (RT-PCR) test is the most commonly utilized test
and considered the current gold standard for diagnosis, the role of chest imaging has been highlighted by several
studies demonstrating high sensitivity of computed tomography (CT). Many have suggested using CT chest as a
first-line screening tool for the diagnosis of COVID-19. However, with advancement of laboratory testing and
challenges in obtaining a CT scan without significant risk to healthcare providers, the role of imaging in diagnosis
has been questioned. Several imaging societies have released consensus statements and guidelines on utilizing
imaging resources and optimal reporting. In this review, we highlight the current evidence on various modalities
in thoracic imaging for the diagnosis of COVID-19 and describe an algorithm on how to use these resources in an
optimal fashion in accordance with the guidelines and statements released by major imaging societies.

1. Introduction
We are amid an unprecedented healthcare pandemic caused by a
novel strain of Coronavirus (SARS-CoV-2) with the disease it causes
named COVID-19. Since the outbreak in Wuhan, China, it has turned
into a global pandemic infecting more than 21 million people with over
760,000 deaths.1 To date, there has been no cure for the disease, though
Remdesevir, an anti-viral drug, has most recently been approved by the
United States Food and Drug Administration (US FDA) on compas
sionate grounds after clinical trials have shown it to reduce disease
burden.2,3 A race to develop a vaccine has started in many countries as
the most effective long-term preventive measure. While scientists
worldwide are still grappling with excruciating details related to the
pathogenesis of the virus, it is clear that the lungs remain the primary
organ of injury. Understandably, there has been a significant interest in
the medical community to study the role of thoracic imaging in COVID19 pneumonia with respect to symptomatology and “confirmatory”
laboratory tests for the virus. Major international imaging societies have

come up with guidelines that take into consideration the current Center
for Disease Control and Prevention (CDC) and World Health Organiza
tion (WHO) recommendations.
In this review, we summarize different imaging guidelines available
to date and put forth an algorithm to guide the appropriate use of im
aging resources based on existing knowledge of the disease. We also
analyze the characteristic imaging features of the disease-related to
temporal progression and emphasize that radiologists should be familiar
with these findings.
2. Clinical features
The incubation period for the disease to manifest is estimated to be
5–14 days.4 Common symptoms of COVID-19 include cough (50–70%),
fever (40–70%), sputum production (18–35%), fatigue (35–40%),
shortness of breath (15–20%), and myalgia or arthralgia (10–15%).5,6
Characteristic early loss of sense of smell and taste has been seen in
many patients, while gastrointestinal symptoms, including diarrhea, are
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also reported.7,8 Indeed, newer manifestations of the disease seem to be
emerging with each passing day, with a hypercoagulable state, strokes in
young patients, and Kawasaki-like autoinflammatory illnesses in chil
dren among the more notable.9,10 A substantial percentage of those
infected can remain asymptomatic (40–50%) or manifest relatively mild
symptoms (40%).11 COVID-19 often presents in a syndromic fashion
with multiple organ involvement including renal failure, vascular
thrombosis, ischemia, respiratory distress and gastrointestinal symp
toms. The affinity of SARS-CoV-2 virus to angiotensin converting
enzyme 2 (ACE-2) receptor has been proposed as a potential mechanism
as a unifying mechanism for such diverse presentation.12
Moderate to severe symptoms are manifested in the remaining pa
tients requiring hospitalization, supplemental oxygenation, and me
chanical ventilation. The disease has proved to be fatal in a small
percentage (<5%) of affected patients. Advanced age, smokers with
structural lung disease, and the presence of comorbidities such as
immunocompromised states, obesity, diabetes, and cardiovascular risk
factors are among the most important parameters associated with worse
prognosis.13 Viral shedding is variable, with infected personnel
remaining infectious to others from 17 to 37 days after acquiring
infection and dependent on the time of symptom onset and high
fever.14,15

the virus in human serum. While these tests have the advantage of being
relatively “rapid” with faster turnaround time, they are limited by
relatively low negative predictive values and high false negatives,
necessitating some to advocate a cautionary approach before relying on
their accuracy.24 Antibody testing is a great tool to assess previous
exposure or infection but cannot reliably diagnose active COVID-19
infection, disease activity or transmissibility.
4. Thoracic imaging in COVID-19
4.1. Computed tomography (CT) of the chest
The role of chest CT in its application to suspected COVID-19 cases
has continued to evolve since the pandemic began. This has primarily
been explored in parallel with our increasing understanding of labora
tory testing, given the rapid spread of infection over a short period.
Earlier studies from China demonstrated high sensitivity for Computed
Tomography (CT) of the chest for COVID-19, suggesting its use as a
potential screening test at the time [Table 1].
Fang et al., in their cohort of 51 patients (29 men, 22 women),
demonstrated that difference in detection rate for initial CT chest was
98% (50/51) compared to 71% for RT-PCR test (36/51).17 While 72%
(36/50) of admitted patients had typical findings of peripheral, sub
pleural ground-glass opacities (GGO), often in the lower lobes, 28% (14/
50) of patients had atypical CT manifestations. One patient had a normal
CT chest. Pulmonary vascular prominence, particularly in the areas of
ground-glass opacities has been identified as a key feature and can be
found in 45% to 90% of cases.25,26
In another study by Tao et al., with a larger cohort of 1014 patients,
the sensitivity of CT chest was higher compared to RT-PCR.18 Of 1014
patients, 59% (601/1014) had positive RT-PCR results, and 88% (888/
1014) had positive chest CT scans. The sensitivity of chest CT in sug
gesting COVID-19 was 97% (95%CI, 95–98%, 580/601 patients) based
on positive RT-PCR results. In patients with negative RT-PCR results,
75% (308/413) had positive chest CT findings; of 308, 48% were
considered as highly likely cases, with 33% as probable cases. By anal
ysis of serial RT-PCR assays and CT scans, the mean interval time be
tween the initial negative to positive RT-PCR results was 5.1 ± 1.5 days;
the initial positive to subsequent negative RT-PCR result was 6.9 ± 2.3
days. 60% to 93% of cases had initial positive CT consistent with COVID19 prior (or parallel) to the initial positive RT-PCR results. 42% (24/57)
cases showed improvement in follow-up chest CT scans before the RTPCR results turned negative.
While these initial studies suggested frequent use of chest CT as a
screening tool, other studies advocated a more conservative approach.
Adam et al., studied 121 patients to assess CT chest findings within two
days of symptom onset and found that 56% (20/36) of the patients had
normal CT chest.27 Barring one patient, almost all of these patients had

3. Laboratory testing
At this time, the reverse transcriptase-polymerase chain reaction
(RT-PCR) test to detect viral RNA remains the most accurate diagnostic
test. The test involves the collection of a nasopharyngeal or throat swab
from suspected individuals and transportation of samples to a laboratory
where real-time RT-PCR is employed on the collected sample. The most
common SARS-CoV-2 genes targeted for testing are RdRp, E gene, and N
gene. E gene is mainly used as a screening tool followed by a confir
matory test using RdRp gene.16
There have been tremendous concerns related to the availability of
adequate testing kits to meet the increasing and often overwhelming
worldwide demands for testing, tracing, and isolating infected in
dividuals. Experience in many countries, including the US, has shown
that laboratory processing times may substantially increase when de
mand for these tests rise. This has augmented the importance of imaging
tests as an alternate diagnostic tool to diagnose suspected COVID-19
patients, a strategy that has been successfully implemented in China
when initial PCR test kits were exhausted early on in the course of the
pandemic. Moreover, PCR testing has its limitation with a relatively low
sensitivity of 60–70%.17,18 Initial test results can thus be falsely negative
in a significant number of patients, and retesting these patients if they
remain symptomatic results in further delays in PCR test turnaround
times. Xiao et al., also demonstrated that up to 21% (15/70) of patients
could have false-negative RT-PCR for SARS-CoV-2, which may be due to
prolonged nucleic acid conversion rather than a recurrence of infec
tion.19 Interestingly, a Bayesian analysis of Chinese studies found a
sensitivity of 77% and specificity of 98% for the Chinese CDC approved
RT-PCR for SARS-CoV-2.20
Moreover, not all RT-PCR tests are equivalent. China approved 11
different tests between January 26 and March 12, 2020. A version of the
test that has been widely used is an RT-PCR adaptation of the CDC assay
and validated by FDA-EUA protocol.21 As the RT-PCR tests require
identifying a primer in different viral genes, the results can be influenced
by genetic variations, mutations and evolution of the virus.22 There is a
need for reference standards in asymptomatic patients so that all RTPCR tests can be standardized and improve overall sensitivity for
screening purposes.23Most of us who have suffered from a common cold
and have antibodies in our blood to many unrelated strains of Corona
viruses, which cause the common cold. This has proved to be a challenge
as far as antibody-based detection tests for the specific strain of coro
navirus implicated in COVID-19. More recently, several newer tests have
been developed to detect the presence of IgG or IgM antibodies against

Table 1
Key imaging findings of COVID-19 pneumonia on computed tomography (CT) of
the chest.
Key imaging findings of COVID-19 pneumonia on computed tomography (CT) of the
chest
Diverse pattern of lung disease on CT with some key imaging features
Distribution
Pattern
Uncommon
findings
Initial findings
Progression
Organization

23

Bilateral, multilobar, subpleural, peripheral and basilar
predominant
Rounded morphology, ground-glass opacities (GGO) and
multilobar consolidations
Mediastinal lymphadenopathy, pleural effusions, cavitations
and pulmonary nodules
Typical pattern
Normal in up to 25% patients
Lobar consolidations, pleural effusions, subpleural blebs and
bullae may develop in severe illness
Early fibrosis and traction bronchiectasis may develop in severe
ARDS in two to four weeks
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isolation33 (Table 2).
Chest CT, therefore, is primarily recommended to be used judiciously
when required as a problem-solving tool only in specific clinical situa
tions that will change management decisions, such as worsening respi
ratory status or if there are concerns for additional diagnoses. The risk
profile of CT scanning in suspected COVID-19 patients is also uniquely
higher than the vast majority of common indications for chest CT
scanning, given concerns regarding infection spread in transit to the CT
scanner and within the CT scanner. This risk also requires an increased
usage of clinical resources for infection control precautions to minimize
infection spread. Additionally, institutions that have been impacted
most severely by the pandemic may have a constraint on imaging re
sources. In this setting, in particular, unneeded chest CTs in COVID-19
suspected patients may limit the ability of other patients to receive a
chest CT in a timely fashion for whom the study is indicated, whether in
the setting of suspected COVID-19 or not. Additionally, the decision to
perform a contrasted study to evaluate for concomitant pulmonary
embolism (PE) versus a non-contrasted study should be at the clinician’s
discretion based on clinical presentation. Covid-19 has been identified
as a prothrombotic state with incidence of venothromboembolism
(VTE).34 In PUIs presenting with chest pain, dyspnea, leg swelling,
tachycardia and elevated D-dimer, CT angiography of the chest should
be considered to evaluate for PE as early initiation of anticoagulation
can be lifesaving.
Several imaging findings have been suggested as typical for COVID19, while other findings are considered atypical as they are seen un
commonly (Table 1).27 Although these findings may hold high sensi
tivity for COVID-19 during a pandemic, one must be cognizant of other
diseases that can cause similar findings. Most viral pneumonias, cryp
togenic organizing pneumonia, and drug-induced lung injury can also
present similarly. Thus, it becomes imperative to endorse a detailed
history and physical examination before settling on the diagnosis of
COVID-19 purely based on chest imaging. Major imaging societies such
as the Radiological Society of North America (RSNA) released an expert
consensus on how to document these findings. This statement has been
endorsed by the American College of Radiology (ACR) and Society of
Thoracic Radiology33 (Table 2).

positive RT-PCR suggesting the presence of infection even when the
chest CT was normal. This study highlighted the variability in the
negative predictive value of the CT.
Interestingly, chest CT may show variable sensitivity depending on
the time when the scan is performed during illness. To look at the
temporal evolution of COVID-19 pneumonia, Wang et al., found the
sensitivity for chest CT to be 84% (95% confidence interval: 73%–92%)
when conducted in 0–5 days of symptom onset. The sensitivity increased
to 99% (95% confidence interval: 93%- 100%) if the chest CT was ob
tained on day 6–11.28 Yu et al. observed that more severe disease had
more lung segment involvement, more extensive opacities, and frequent
findings of interlobular septal thickening, air bronchograms, and even
pleural effusions.29 Another study by Pan et al. showed similar findings
with greater severity peaking at day 10 of illness.30
Inui et al., studied the chest CT findings on cases from “Diamond
Cruise Ship” and found that imaging abnormalities were more common
in symptomatic (22/28 = 79%) compared to asymptomatic (41/76 =
54%) laboratory-confirmed COVID-19 patients. However, ground-glass
opacities were common in asymptomatic patients (83%) compared to
consolidative opacities in symptomatic patients (41%).31 Meng et al.,
from Wuhan, studied chest CT evolution in asymptomatic laboratoryconfirmed COVID-19 patients for over 54 days and found similar find
ings of GGO and interlobular septal thickening. They found that 27%
(16/58) of patients eventually became symptomatic and had abnormal
inflammatory markers and lymphopenia.32
Ultimately, key imaging features of COVID-19 on chest CT are now
understood to include bilateral (multilobar), peripheral, and basilar
distribution, of opacities with rounded morphology. Pertinent imaging
negatives to note are the absence of lymphadenopathy, effusions, cavi
tation, or nodules, which potentially suggest alternative diagnoses
(Table 1).27 However, the imaging presentation is often variable, and the
commonly associated imaging features are inherently non-specific. Im
aging features alone cannot differentiate COVID-19 from other viral
pneumonias. Additionally, diagnoses such as cryptogenic organizing
pneumonia, eosinophilic pneumonia, and pulmonary infarcts can also
present with these imaging features. Given this lack of specificity in
imaging features when present and the variable sensitivity of chest CT
related to phase of the disease the patient is scanned in, CT is not
considered an effective screening tool by the major radiology societies.
Instead, clinical symptomology and PCR laboratory findings will decide
whether a patient is likely positive for COVID-19 and requires

4.2. Our experience with progression of COVID-19 disease and CT
imaging
Based on our experience in New York and Cleveland, initial findings
in laboratory-confirmed COVID-19 patients include typical patterns of
peripheral, patchy ground-glass opacities in most cases (Fig. 1A–B).
Some patients experienced rapid progression to acute respiratory
distress syndrome (ARDS) with worsening consolidation more pro
nounced in the lower lobes (Fig. 2A–B). Secondary bacterial pneumonia
has been observed in autopsy findings and can manifest as lobar
consolidation35 (Fig. 3A–B). Since the pathophysiology of lung injury is
severe diffuse alveolar damage (DAD) that starts with the exudative
phase and evolves into a fibroproliferative phase, a longer in-hospital
follow-up on these patients has demonstrated persistent ground-glass
opacities with organized focal consolidations (Fig. 4A–B). In severe
cases, early-onset extensive fibrosis and bronchiectasis have been
observed (Fig. 5). In patients with severe ARDS who develop secondary
bacterial and fungal infections, necrotizing cavitary lesion (Fig. 6), and
large bullous disease with pneumothoraces (Fig. 7A–B) have been
observed. These patterns highlight the importance of CT imaging during
the clinical course, especially if a secondary infection or COVID-19
related complication is suspected. However, there is always a logistic
constraint in obtaining CT imaging, which includes intrahospital transit,
decontamination of the CT room, and risk of exposure to healthcare
providers. This may become further complicated in the future when
there are sporadic cases of unconfirmed COVID-19, which can lead to
increased exposure to radiology technician and CT imaging.

Table 2
RSNA expert consensus statement on structured reporting for chest CT in COVID19.
RSNA expert consensus statement on structured reporting for chest CT in COVID-1933
Classification

Rationale

Suggested reporting language

Typical

Imaging features with high
specificity and commonly
reported for COVID-19
pneumonia

Indeterminate

Non-specific imaging features
reported in COVID-19
pneumonia

Atypical

Uncommon or imaging features
not reported in COVID-19
pneumonia

Negative

No features of pneumonia

“Commonly reported imaging
features of COVID-19 pneumonia
are present. Other processes such
as influenza pneumonia and
organizing pneumonia, as can be
seen with drug toxicity and
connective tissue disease can
cause a similar imaging pattern.”
“Imaging features can be seen in
COVID-19 pneumonia, though
are non-specific and can occur
with a variety of infectious and
non-infectious processes.”
“Imaging features are atypical or
uncommonly reported for COVID19 pneumonia. Alternative
diagnosis should be considered.”
“No CT findings to indicate
pneumonia”
(Note: CT may be negative in
initial stage of COVID-19)
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Fig. 1. Initial imaging findings in COVID-19. (A) Chest CT shows bilateral, peripheral, patchy ground-glass opacities in both lungs, right worse than left. (B) Portable
CXR is near normal with very subtle peripheral opacities in the mid lung zones and left base.

Fig. 2. Rapid progression to ARDS in COVID-19. (A) Chest CT shows worsening consolidation which is more pronounced in the bilateral lower lobes. (B) Portable
CXR obtained a few days prior to CT shows early development of consolidative changes in the bilateral posterior lung bases.

Fig. 3. Secondary bacterial pneumonia in patient of COVID-19. (A) Chest CT shows dense right lower lobe consolidation with air-bronchograms due to secondary
bacterial pneumonia. Mild consolidation is seen in the left lower lobe. (B) Portable CXR obtained a day later, shows progression of dense consolidation in the right
lower lobe as well as right upper lobe and left lung.

4.3. Role of chest radiography in the diagnosis of COVID-19

pneumonia in immunocompetent patients, despite known low sensi
tivity. A recent multi-site study of 636 symptomatic patients from the
greater New York area with confirmed Covid-19 demonstrated a normal

Chest radiography (CXR) plays a role in the imaging management of
25
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Fig. 4. Persistent opacities with imaging signs of early organization. (A) Chest CT shows persistent ground-glass opacities with lobular areas of sparing in the nondependent areas and organized consolidations in the dorsal/dependent portions of both lungs. (B) Portable CXR obtained a few days after CT, shows progression of
dense consolidations in both lungs with mid and lower zone predominance.

Fig. 6. Necrotizing pneumonia with COVID-19. CT chest shows a cavitary
lesion in the middle lobe suggestive of necrotizing pneumonia with lung abscess
due to secondary bacterial pneumonia. There are diffuse ground-glass opacities
and lower lobe consolidations due to COVID-19. Note, small right
pneumothorax.

Fig. 5. Early-onset extensive fibrosis and bronchiectasis in COVID-19. Chest CT
shows peribronchial fibrotic consolidations and ground-glass opacities with
development of traction bronchiectasis mainly in the right lower and mid
dle lobes.

accessibility. Particularly in institutions that are constrained in CT im
aging resources, it can also preclude the need for additional CTs. The
associated increased risk of infection in transporting a patient to the
scanner, or infection spread within the scanner, and subsequent
mandatory decontamination measures, are also mitigated.40,41

chest radiograph in 58.3% (371/636) of patients and a normal or only
mildly abnormal chest radiograph in 89% (566/636) of patients.36,37 In
patients with COVID, the indication for CXR are no different than in
other pneumonias. CXR is considered appropriate as an initial imaging
diagnostic test in patients with lower respiratory tract infection,
including those with suspicion for COVID infection. CXR should not be
indicated to rule out COVID-19 infection due to its low sensitivity. Wong
et al., observed the sensitivity of CXR to be 69% (44/64) compared to
91% (58/64) for RT-PCR in their cohort of 64 COVID positive patients.38
Peripheral, lower lobe predominant consolidations and ground-glass
opacities were the most common findings. Ippolito et al., demon
strated that out of 68 patients who had a CT chest after a CXR with a
mean lag time of 2 days; the CXR was able to detect abnormal findings in
89.7% (61/68) of the patients. They also had 10% (7/68) of patients
who had negative CXR but were found to have GGO on CT scan.39 A
normal CXR does not rule out the possibility of pneumonia in general
and, expressly, does not exclude the diagnosis of pneumonia in patients
with suspected COVID. However, chest radiography is valuable to image
the evolution of COVID-19 pneumonia, which can be followed using
serial CXR. The advantages of CXR include portability and easy

4.4. Lung ultrasonography
The current guidelines in use by RSNA, Fleischner, and ACR /STR for
lung imaging in COVID-19 do not prescribe any role for lung ultraso
nography. The authors would like to emphasize that point-of-care lung
ultrasonography is an investigational tool in imaging COVID-19 patients
at this time. Small case series have suggested pleural line irregularities,
multiple B-lines and subpleural consolidations and absence of pleural
effusions as common findings in COVID-19.42,43 Zhang et al. found Blines in 100% (n = 28) of their patients while thickened pleural lines in
60.7% and subpleural consolidations in 67% of their patients.44 While
data is limited to small case series, there is no larger studies to assess the
accuracy of lung ultrasonography in COVID-19 and the evidence for its
routine use for diagnosis of COVID-19 is scant. There is a role for ul
trasound in evaluating complications related to pneumonia such as
26
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Fig. 7. Large bullous disease with pneumothorax in COVID-19. (A) Chest CT shows bullae in the anterior basilar segment right lower lobe and superior lingula, with
dense consolidations in both lower lobes. (B) Follow-up chest CT shows development of a large multi-loculated, tension right pneumothorax due to ruptured bulla,
resulting in contralateral mediastinal shift.

symptoms and high pre-test probability of COVID-19 pneumonia.41
Imaging may also be utilized for assessment of disease progression or
complications in a resource-constrained environment.

evaluating for parapneumonic effusions and/or empyema, though these
are not specific for COVID-19.
5. Current guidelines issued by major imaging societies

6. Diagnostic algorithm based on RT-PCR testing and imaging

In the light of the COVID-19 pandemic and emerging evidence on
serologic and imaging diagnosis of COVID-19 pneumonia, all major
imaging societies have released expert consensus statement and guide
lines. The Society of Thoracic Radiology (STR) and the American Society
of Emergency Radiology (ASER) released a position statement on March
11, 2020, on the utility of CT chest as a screening tool for COVID-19.
They do not recommend routine CT chest for screening patients under
investigation (PUI) for COVID-19 and suggest using it to evaluate
complications such as abscess or empyema.45
The American College of Radiology (ACR) in concordance with the
CDC released guidelines echoing similar sentiments in avoiding CT chest
as a first-line screening test to diagnose COVID-19 pneumonia.46 They
recommend the limited role of CT chest in symptomatic and hospitalized
patients who fulfill clinical indications for a CT scan.47 Alternatively,
they suggest using portable CXR as it is quick, efficient, and easy to
decontaminate. The ACR also cautions against using CT chest to guide
decisions on RT-PCR testing for COVID-19 or quarantining patients, as
normal imaging does not exclude infection, and abnormal CT imaging is
not specific for COVID-19 diagnosis. They do, however, suggest a
possible role of CT chest for diagnosis and management of COVID-19 in
critically ill patients or if RT-PCR is not available.46
The Radiological Society of North America (RSNA) in endorsement
with STR, recommended not using CT chest to screen for COVID-19 and
suggested four categories for standardized CT chest reporting language
for COVID-19.33 In anticipation of mixed and atypical imaging findings
due to either complications or co-infection, the interpretation towards
COVID-19 may become challenging. Table 2 highlights the RSNA sug
gested reporting language for COVID-19 imaging.33 The RSNA recom
mends using “viral pneumonia” as an alternative term for incidentally
discovered imaging findings that are compatible with COVID-19. They
also recommend radiologists to follow ACR Practice Parameter and
Communication for Diagnostic Imaging Findings for reporting.48
The Fleischner Society has also released a multinational statement on
using chest imaging during the COVID-19 pandemic based on the
severity of illness, resource availability, and pre-test probability for
COVID-19.41 They recommend against the use of any imaging in mild
COVID-19 case while reserving imaging for patients with severe or
progressive respiratory failure. In a resource-constrained situation, im
aging may be utilized for triaging patients with moderate to severe

We propose a diagnostic algorithm utilizing RT-PCR and thoracic
imaging in accordance with the expert consensus and statements from
major imaging societies (Fig. 8). For most patients, imaging has little
practical influence on their disposition. RT-PCR testing has remained the
reference standard and initial screening test of choice. We use clinical
symptoms to guide care in most cases, given that 20–25% of CT scans
will be normal in the early stages of the disease.
The current standard is to test for the respiratory syncytial virus
(RSV), Influenza A, and B as part of the nasopharyngeal swab for COVID19 to evaluate for alternate etiology. If RT-PCR is positive for COVID-19,
clinical symptoms are used to triage patients to quarantine at home or
admit to the hospital. No imaging is advised at this stage as it will not
change management in most individuals.
If RT-PCR is negative for COVID-19, no specific imaging recom
mendation is made. RT-PCR is generally repeated 5–6 days after nega
tive results if the patient remains symptomatic (the approach may not
always be practical with limited access to testing).
In symptomatic patients, if RT-PCR status is unknown or pending, a
portable CXR can be considered as an initial test of choice. If typical
features are present on CXR, a CT chest is not recommended. The de
cision to scan the patient can be made based on the presence of sus
pected radiographic abnormalities such as lung abscess formation,
empyema, pneumothorax, etc. In symptomatic patients with normal
chest radiographs who have a high pre-test probability of COVID-19,
high-risk individuals such as elderly, smokers, history of chronic lung
disease, or those with high suspicion for clinical worsening, a CT chest
may be considered for the diagnosis of COVID-19.
6.1. Key points related to Imaging of suspected COVID-19 patients
• CXR is the initial imaging modality of choice in every suspected case
regardless of laboratory status.
• If CT is indicated for reasons as previously stated, a non-contrast CT
chest should be the standard test.
• Referring services should enter discriminators such as “COVID-19
positive” or “COVID-PUI” when ordering the CT chest.
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Fig. 8. Proposed algorithm for imaging in patients with suspected COVID-19 pneumonia.
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6.2. Reporting: radiologist responsibilities
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• Radiologists should familiarize themselves with the most common
imaging findings of COVID-19 pneumonia.
• Radiologists must remember that the imaging findings are nonspecific and may be secondary to other viral or infectious patho
gens or other non-infectious disease processes. To that end, with the
relevant imaging findings, an appropriate format for reporting must
be used such as, “the imaging findings are consistent with an infec
tious process, possibly viral” rather than making a specific reference
to COVID-19 or another specific pathogen.
• As with the imaging findings of any lung illness, knowing the clinical
context is essential to providing a probable or correct diagnosis.
Diagnostic concern about a specific organism should be communi
cated directly with the patient’s clinician, allowing him/her to put
that in the proper context.
7. Conclusion
As the diagnostic techniques for COVID-19 continue to evolve, lab
oratory confirmation of COVID-19 remains the initial screening test of
choice with a limited role of CT chest in diagnosis or screening. CXR
appears to be a reasonable imaging modality of choice in patients with
suspected and pending RT-PCR for COVID-19 (PUI). Imaging may be
considered to triage patients in the resource-constrained environment as
recommended by the Fleischner Society expert statement.41 The ACR,
CDC, RSNA, and STR at this point do not see the advantage of screening
CT as it is non-specific and will not change management and quarantine
status, which is dictated by the patient’s history and symptoms. Initial
CT chest can be negative in up to 25% of patients with COVID-19;
however, sensitivity increases with disease progression with abnormal
findings in 95% of cases after 5–6 days of infection. CT chest should only
be performed if there is a clinical indication for it in accordance with
ACR appropriateness criteria for acute respiratory illness in immuno
competent patients.47
In hospitalized patients, CXR remains the imaging modality of choice
as a baseline imaging and monitoring disease progression and compli
cations. CT chest may be considered for evaluation of complications as
superimposed bacterial pneumonia, abscess, or empyema. Point of care
lung ultrasonography for the diagnosis of COVID-19 remains an inves
tigational tool and is currently not recommended as a diagnostic test by
major professional imaging societies.
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